Oncology Vol 29 No 3

The Era of Immuno-Oncology: Are We There Yet?

March 15, 2015

The next few years hold great promise, as new agents emerge and others consolidate their place on our shelves. We will be forced to rethink strategies and redefine management as a new era of immuno-oncology dawns.

Genomic Testing in Colorectal Cancer: How Much Is Enough?

March 15, 2015

The identification and characterization of gene signatures, driver events, and pharmacogenomics in molecularly homogeneous subsets of patients is likely to advance effective drug development strategies in colorectal cancer.

Costs and Effectiveness of Genomic Testing in the Management of Colorectal Cancer

March 15, 2015

Numerous genomic tests are available for use in colorectal cancer, with a widely variable evidence base for their effectiveness and cost-effectiveness. In this review, we highlight many of these tests, with a focus on their proposed role, the evidence base to support that role, and the associated costs and risks.